EUVIMEDEUVIMED entdecken
Vergleichsstudie

Durability of Adalimumab and Infliximab in Children With Crohn’s Disease: A Nationwide Comparison From the epi-IIRN Cohort

Ohad Atia iD, Chagit Friss, Gili Focht, Ramit Magen Rimon, Natan Ledderman, Amir Ben-Tov, Yiska Loewenberg Weisband, Eran Matz, Yuri Gorelik, Yehuda Chowers, Iris Dotan, Dan Turner

Inflammatory Bowel Diseases · 04.11.2024 · 30 (11) · 2097-2104

DOI: 10.1093/ibd/izad301 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 08.01.2024. Verfasst von Ohad Atia und 11 weiteren Autor:innen. Beteiligte Einrichtung: Juliet Keidan Institute of Pediatric Gastroenterology Hepatology and Nutrition, Shaare Zedek Medical Center, The Hebrew University of Jerusalem, Isra…. Hauptthemen laut MEDLINE: Crohn Disease, Adalimumab, Infliximab. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Leona M. and Harry B. Helmsley Charitable Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In a nationwide cohort, we aimed to compare the durability of infliximab and adalimumab as first biologic treatment in children with Crohn’s disease (CD), stratified as combotherapy or monotherapy.

Methods

We used data from the epi-IIRN cohort that includes all patients with inflammatory bowel diseases in Israel. Durability was defined as consistent treatment without surgery or treatment escalation. All comparisons followed stringent propensity-score matching in Cox proportional hazard models.

Results

Of the 3487 children diagnosed with CD since 2005, 2157 (62%) received biologics (1127 [52%] infliximab, 964 [45%] adalimumab and 52 [2%] vedolizumab as first biologic), representing a higher proportion than that among adults diagnosed during the same time period (5295 of 15 776 [34%]; P < .001). Time from diagnosis to initiation of biologic was shorter in pediatric-onset compared with adult-onset disease (median time during the last 3 years was 2.7 months [interquartile range 1.2-5.4] vs 5.2 months [2.6-8.9]; P < .001). The durability of adalimumab monotherapy after 1 and 5 years from initiation of treatment was better than infliximab monotherapy (79%/54% vs 67%/37%, respectively; n = 452 matched children; hazard ratio [HR], 1.7; 95% confidence interval [CI], 1.3-2.3; P < .001), while in those treated with combotherapy, durability was similar (94%/66% with infliximab vs 90%/54% with adalimumab; n = 100; HR, 1.7; 95% CI, 0.9-3.3; P = .1). Durability was higher in children treated with infliximab combotherapy vs infliximab monotherapy (87%/45% vs 75%/39%; n = 440; HR, 1.4; 95% CI, 1.1-1.8; P = .01). The durability of adalimumab monotherapy was similar to infliximab combotherapy (83%/53% vs 89%/56%, respectively; n = 238; HR, 0.9; 95% CI, 0.7-1.2; P = .4).

Conclusion

Our results support using adalimumab monotherapy as a first-line biologic in children with CD. When infliximab is used, combotherapy may be advantageous over monotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Crohn DiseaseAdalimumabInfliximabHumansMaleFemaleChildIsraelAdolescentGastrointestinal AgentsProportional Hazards ModelsCohort StudiesAntibodies, Monoclonal, HumanizedTreatment OutcomePropensity ScoreDrug Therapy, CombinationAnti-Inflammatory Agents

Stichwörter der Autor:innen

Crohn’s diseasebiologicschildrendurabilityoutcomes

Substanzen

AdalimumabInfliximabGastrointestinal AgentsAntibodies, Monoclonal, HumanizedvedolizumabAnti-Inflammatory Agents

Autor:innen und Institutionen

  • Juliet Keidan Institute of Pediatric Gastroenterology Hepatology and Nutrition, Shaare Zedek Medical Center, The Hebrew University of Jerusalem, Israel.
  • Pediatric Gastroenterology & Nutrition institute, Ruth Rappaport Children's Hospital, Rambam Medical Center, Faculty of Medicine, Technion, Haifa, Israel.
  • Meuhedet Health Services, Tel-Aviv, Israel.
  • Kahn Sagol Maccabi Research and Innovation Center, Maccabi Healthcare Services, Tel-Aviv, Israel.
  • The Faculty of Medicine, Tel Aviv University, Israel.
  • Clalit Health Services, Clalit Research Institute, Tel-Aviv, Israel.

ORCID-Profile: Ohad Atia

Förderung

  • Leona M. and Harry B. Helmsley Charitable Trust

Zitieren

APA

Atia, O., Friss, C., Focht, G., Magen Rimon, R., Ledderman, N., Ben-Tov, A., Loewenberg Weisband, Y., Matz, E., Gorelik, Y., Chowers, Y., Dotan, I., & Turner, D. (2024). Durability of Adalimumab and Infliximab in Children With Crohn’s Disease: A Nationwide Comparison From the epi-IIRN Cohort. Inflammatory Bowel Diseases, 30(11), 2097-2104. https://doi.org/10.1093/ibd/izad301

Vancouver

Atia O, Friss C, Focht G, Magen Rimon R, Ledderman N, Ben-Tov A, et al. Durability of Adalimumab and Infliximab in Children With Crohn’s Disease: A Nationwide Comparison From the epi-IIRN Cohort. Inflammatory Bowel Diseases. 2024;30(11):2097-2104. doi:10.1093/ibd/izad301

BibTeX
@article{Atia2024,
  author = {Atia, Ohad and Friss, Chagit and Focht, Gili and Magen Rimon, Ramit and Ledderman, Natan and Ben-Tov, Amir and Loewenberg Weisband, Yiska and Matz, Eran and Gorelik, Yuri and Chowers, Yehuda and Dotan, Iris and Turner, Dan},
  title = {Durability of Adalimumab and Infliximab in Children With Crohn’s Disease: A Nationwide Comparison From the epi-IIRN Cohort},
  journal = {Inflammatory Bowel Diseases},
  year = {2024},
  volume = {30},
  number = {11},
  pages = {2097--2104},
  doi = {10.1093/ibd/izad301}
}
Kostenlos starten →